SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company has granted Norgine Pharma UK Limited, an affiliate of Norgine, a leading European specialty pharmaceutical company, an exclusive license for the commercial rights to the combination of tobevibart and elebsiran for the treatment of chronic hepatitis delta (CHD) in Europe, Australia and New Zealand. 1 Per the terms of the agreement, Vir Biotechnology will receive an initial reimbursement payment of EUR 55 m ...

Core Insights - Vir Biotechnology, Inc. announced positive results from the Week 48 endpoint analysis of its Phase 2 SOLSTICE trial for chronic hepatitis delta (CHD) [1] Group 1: Trial Results - Participants receiving a monthly dose of the combination of tobevibart and elebsiran achieved robust and sustained rates of hepatitis delta virus (HDV) RNA target not detected (TND) [1] - The combination treatment was effective even among participants with cirrhosis and high baseline HDV RNA levels [1]